Johnson & Johnson (JNJ) is expanding a recall of over-the-counter drugs including Tylenol and Motrin IB because of a musty or moldy smell.

The McNeil Consumer Healthcare business said it is recalling 21 lots of over-the-counter drugs sold in the U.S., Puerto Rico, Fiji, Guatemala, the Dominican Republic, Trinidad and Tobago, and Jamaica.

The drugs that are being recalled include Benadryl, Children's Tylenol, Motrin IB, Tylenol Extra Strength, Tylenol Day & Night, and Tylenol PM.

The company has already made a large recall of those drugs and over-the-counter products, saying about 70 people noticed the smell. Some of them got sick, with symptoms including nausea, stomach pain, vomiting and diarrhea. The odor was linked to a chemical in shipping pallets and traced to a facility in Puerto Rico.

The company had planned to stop shipping those products on wooden pallets treated with the chemical, and asked its suppliers to do the same.

Johnson & Johnson said the latest recall applies to products made before the January recall.

Sales of J&J pain relievers are dropping as a string of recalls appears to have made consumers wary of once-sterling brands such as Tylenol and Motrin.

That wariness and the huge amount of products pulled off store shelves together look to be costing J&J tens of millions of dollars a month.

The string of recalls is an embarrassment for a company that set the standard on how to do it correctly when it rushed to pull bottles of Tylenol — deliberately poisoned by someone who was never caught — off store shelves in the early 1980s.

This time, the culprit appears to be a lack of internal quality control. That's harder to forgive, particularly given that the public has little tolerance for mistakes or carelessness involving products for children, said analyst Steve Brozak of WBB Securities.

"This is pain by a thousand cuts," Brozak said.

Data from market research firm SymphonyIRI Group show sales of New Brunswick, N.J.-based J&J's pain reliever pills fell 56% in the four weeks ending June 13, compared to a year earlier.

Its figures show that U.S. sales of pain-relieving tablets, gelcaps and other types of pills, including multiple strengths of Tylenol and Motrin, plunged to $20.9 million in that four-week period, putting the company behind rivals Bayer Consumer Health and Wyeth Labs. Sales of private-label, or store brands, benefited the most from Johnson & Johnson's fall, jumping 23% to $51.9 million.

Meanwhile, sales in the smaller category of liquid pain relievers, such as Children's Tylenol, fell 96%, to just $630,000. Those figures do not include sales at Walmart, gas station stores and club stores.

Together, that amounts to tens of millions of dollars in revenue lost in just one month — and a big hit to the reputation of the maker of iconic products such as Johnson & Johnson's baby shampoo and Band-Aids.

A Johnson & Johnson spokeswoman said the company had no comment beyond its announcement of the latest recall.

Food and Drug Administration spokeswoman Elaine Gansz Bobo said the agency continues to work with McNeil on all the product recalls.

"We do not see any serious health risk to the public," she said.

Gansz Bobo said she did not know of any other company that had eight medicine recalls in less than a year.

"It certainly is quite a few, and something that we hope is not repeated by other companies," she told The Associated Press.

• Associated Press-USA Today